1 Galle PR, Finn RS, Qin S et al. Patient-reported outcomes with
atezolizumab plus bevacizumab versus sorafenib in patients with
unresectable hepatocellular carcinoma (IMbrave150): an open-label,
randomised, phase 3 trial. Lancet Oncol. 2021; 22: 991–1001.
2 Hsu C, Rimassa L, Sun HC, Vogel A, Kaseb AO. Immunotherapy in
hepatocellular carcinoma: evaluation and management of adverse
events associated with atezolizumab plus bevacizumab. Ther. Adv.
Med. Oncol. 2021; 13: 17588359211031141.
3 Tada T, Kumada T, Hiraoka A et al. Safety and efficacy of
atezolizumab plus bevacizumab in elderly patients with hepatocellular
carcinoma: A multicenter analysis. Real-life Practice Experts for HCC
(RELPEC) Study Group and the Hepatocellular Carcinoma Experts
from 48 clinics in Japan (HCC 48) Group. Cancer Med. 2022; 11:
3796–808.
4 Vithayathil M, D’Alessio A, Fulgenzi CAM et al. Impact of older
age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma. Liver Int. 2022; 42: 2538–47.
5 D’Alessio A, Fulgenzi CAM, Nishida N et al. Preliminary evidence
of safety and tolerability of atezolizumab plus bevacizumab in
patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study. Hepatology. 2022; 76: 1000–12.
6 Casak SJ, Donoghue M, Fashoyin-Aje L et al. FDA approval summary: atezolizumab plus bevacizumab for the treatment of patients
with advanced unresectable or metastatic hepatocellular carcinoma.
Clin. Cancer Res. 2021; 27: 1836–41.
7 Tian JC, Liu H, Yan LJ et al. Adverse events of immune checkpoint
inhibitors in hepatocellular carcinoma: a systemic review and metaanalysis. Clin. Exp. Med. 2022. https://doi.org/10.1007/s10238-02200938-6.
8 EASL clinical practical guidelines management of alcoholic liver disease. J. Hepatol. 2012; 57: 399–420.
9 Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment
for hepatocellular carcinoma. Semin. Liver Dis. 2010; 30: 52–60.
10 Campani C, Bamba-Funck J, Campion B et al. Baseline ALBI score
and early variation of serum AFP predicts outcomes in patients with
13
14
15
16
17
18
19
20
21
22
HCC treated by atezolizumab-bevacizumab. Liver Int. 2023; 43:
708–17.
Tanaka T, Takata K, Yokoyama K et al. Pretreatment modified
albumin-bilirubin grade is an important predictive factor associated
with the therapeutic response and the continuation of atezolizumab
plus bevacizumab combination therapy for patients with unresectable
hepatocellular carcinoma. Curr. Oncol. 2022; 29: 4799–810.
Unome S, Imai K, Takai K et al. Changes in ALBI score and
PIVKA-II within three months after commencing atezolizumab plus
bevacizumab treatment affect overall survival in patients with
unresectable hepatocellular carcinoma. Cancers (Basel). 2022; 14:
6089.
Haratani K, Hayashi H, Chiba Y et al. Association of immune-related
adverse events with nivolumab efficacy in non-small-cell lung cancer.
JAMA Oncol. 2018; 4: 374–8.
Hsiehchen D, Naqash AR, Espinoza M et al. Association between
immune-related adverse event timing and treatment outcomes. Onco.
Targets. Ther. 2022; 11: 2017162.
Chennamadhavuni A, Abushahin L, Jin N, Presley CJ, Manne A.
Risk factors and biomarkers for immune-related adverse events: a
practical guide to identifying high-risk patients and rechallenging
immune checkpoint inhibitors. Front. Immunol. 2022; 13: 779691.
Park R, Lopes L, Saeed A. Anti-PD-1/L1-associated immune-related
adverse events as harbinger of favorable clinical outcome: systematic
review and meta-analysis. Clin. Transl. Oncol. 2021; 23: 100–9.
Spagnolo P, Chaudhuri N, Bernardinello N, Karampitsakos T,
Sampsonas F, Tzouvelekis A. Pulmonary adverse events following
immune checkpoint inhibitors. Curr. Opin. Pulm. Med. 2022; 28: 391–8.
Hiraoka A, Kumada T, Tada T et al. Clinical predictor of urinary protein as adverse event associated with atezolizumab plus bevacizumab
treatment for unresectable hepatocellular carcinoma. Real-life Practice
Experts for HCC (RELPEC) Study Group; HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Oncology. 2022;
100: 645–54.
Suzuki H, Iwamoto H, Shimose S et al. Case Report: Exacerbation of
varices following atezolizumab plus bevacizumab treatment of hepatocellular carcinoma: A case series and literature review. Front.
Oncol. 2022; 12: 948293.
Furusawa A, Naganuma A, Suzuki Y et al. Two cases of rapid progression of esophageal varices after atezolizumab-bevacizumab treatment for
hepatocellular carcinoma. Clin. J. Gastroenterol. 2022; 15: 451–9.
Larrey E, Campion B, Evain M et al. A history of variceal bleeding
is associated with further bleeding under atezolizumab-bevacizumab
in patients with HCC. Liver Int. 2022; 42: 2843–54.
Abou-Alfa GK, Lau G, Kudo M et al. Tremelimumab plus
Durvalumab in unresectable hepatocellular carcinoma. NEJM Evi.
2022; 1. https://doi.org/10.1056/EVIDoa2100070.
JGH Open: An open access journal of gastroenterology and hepatology 7 (2023) 476–481
© 2023 The Authors. JGH Open published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
481
23979070, 2023, 7, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/jgh3.12932 by Kobe University, Wiley Online Library on [01/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License
Y Yano et al.
...
論文の公開元へ
